Maplelane Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Maplelane Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2	Closed	–	–	131
2018 Q4	$0	Buy	+2	New	+$213	﹤0.01%	144

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Maplelane Capital's LGND Position: Q1 2019 in Review

Maplelane Capital sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 2 shares.

Maplelane Capital first reported a position in LGND in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

Maplelane Capital reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Maplelane Capital sold 2 Ligand Pharmaceuticals shares in Q1 2019.
Maplelane Capital first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 1 quarter.
Maplelane Capital's Ligand Pharmaceuticals position peaked at $0 in Q4 2018.
330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Maplelane Capital's 13F filing for Q1 2019, filed 15 May 2019.